Drugs / IMJ995
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05168748 | Jan 2023 → Aug 2026 | acute lymphoblastic leukemia | Novartis Pharmaceuticals | Withdrawn | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IMJ995 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05168748 ↗ |
| Route | Intravenous | “Single intravenous administration of IMJ995” NCT05168748 ↗ |